2020 has been an unbelievably difficult year for everyone and has thrown special obstacles in the way of startup founders. Doing labwork, pitching investors, conducting trials: it can seem like nothing is easy or even possible. Yet you can make progress. Who could confirm this better than Harith Rajagopalan, CEO of Fractyl? Fractyl, whose technology treats patients with type 2 diabetes, received an Investigational Device Exemption from the FDA this June; and in August closed a $55 million round to fund global clinical trials. How did Harith do it?